GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS
Background: Gilteritinib (XOSPATA ®, Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ADMIRAL trial, gilteritinib was compared with the standard of care in (R/R) acute myeloid leukemia...
| Những tác giả chính: | , , , , , , , |
|---|---|
| Định dạng: | Bài viết |
| Ngôn ngữ: | English |
| Được phát hành: |
PAGEPress Publications
2023-04-01
|
| Loạt: | Mediterranean Journal of Hematology and Infectious Diseases |
| Những chủ đề: | |
| Truy cập trực tuyến: | http://www.mjhid.org/index.php/mjhid/article/view/5305 |